These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

520 related articles for article (PubMed ID: 31449975)

  • 1. A new dawn for managing dyslipidemias: The era of rna-based therapies.
    Macchi C; Sirtori CR; Corsini A; Santos RD; Watts GF; Ruscica M
    Pharmacol Res; 2019 Dec; 150():104413. PubMed ID: 31449975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Role of RNA-Targeted Therapeutics to Reduce ASCVD Risk: What Have We Learned Recently?
    Miname MH; Rocha VZ; Santos RD
    Curr Atheroscler Rep; 2021 Jun; 23(8):40. PubMed ID: 34146170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid-Lowering Agents.
    Hegele RA; Tsimikas S
    Circ Res; 2019 Feb; 124(3):386-404. PubMed ID: 30702996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antisense oligonucleotides for the treatment of dyslipidaemia.
    Visser ME; Witztum JL; Stroes ES; Kastelein JJ
    Eur Heart J; 2012 Jun; 33(12):1451-8. PubMed ID: 22634577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Promise of PCSK9 and Lipoprotein(a) as Targets for Gene Silencing Therapies.
    Chan DC; Watts GF
    Clin Ther; 2023 Nov; 45(11):1034-1046. PubMed ID: 37524569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A; Watts GF
    Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Moving Targets: Recent Advances in Lipid-Lowering Therapies.
    Larsen LE; Stoekenbroek RM; Kastelein JJP; Holleboom AG
    Arterioscler Thromb Vasc Biol; 2019 Mar; 39(3):349-359. PubMed ID: 30676072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins.
    Kim K; Ginsberg HN; Choi SH
    Diabetes Metab J; 2022 Jul; 46(4):517-532. PubMed ID: 35929170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role of Antisense Therapies Targeting Lipoprotein(a).
    Plakogiannis R; Sorbera M; Fischetti B; Chen M
    J Cardiovasc Pharmacol; 2021 Jul; 78(1):e5-e11. PubMed ID: 34232223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Familial hypercholesterolemia and elevated lipoprotein(a): double heritable risk and new therapeutic opportunities.
    Vuorio A; Watts GF; Schneider WJ; Tsimikas S; Kovanen PT
    J Intern Med; 2020 Jan; 287(1):2-18. PubMed ID: 31858669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New Strategies for Lowering Low Density Lipoprotein Cholesterol for Cardiovascular Disease Prevention.
    Gaine SP; Quispe R; Patel J; Michos ED
    Curr Cardiovasc Risk Rep; 2022 Sep; 16(9):69-78. PubMed ID: 36213094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipid-Lowering Biotechnological Drugs: from Monoclonal Antibodies to Antisense Therapies-a Clinical Perspective.
    Jia X; Liu J; Mehta A; Ballantyne CM; Virani SS
    Cardiovasc Drugs Ther; 2021 Dec; 35(6):1269-1279. PubMed ID: 32997212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Traditional and novel non-statin lipid-lowering drugs.
    Jain P
    Indian Heart J; 2024 Mar; 76 Suppl 1(Suppl 1):S38-S43. PubMed ID: 37979722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention.
    Michaeli DT; Michaeli JC; Albers S; Boch T; Michaeli T
    Am J Cardiovasc Drugs; 2023 Sep; 23(5):477-495. PubMed ID: 37486464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis.
    Wright RS; Ray KK; Raal FJ; Kallend DG; Jaros M; Koenig W; Leiter LA; Landmesser U; Schwartz GG; Friedman A; Wijngaard PLJ; Garcia Conde L; Kastelein JJP;
    J Am Coll Cardiol; 2021 Mar; 77(9):1182-1193. PubMed ID: 33663735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New clinical perspectives of hypolipidemic drug therapy in severe hypercholesterolemia.
    Stefanutti C; Morozzi C; Di Giacomo S
    Curr Med Chem; 2012; 19(28):4861-8. PubMed ID: 22963620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Prespecified Secondary End Points in ORION 1.
    Ray KK; Stoekenbroek RM; Kallend D; Leiter LA; Landmesser U; Wright RS; Wijngaard P; Kastelein JJP
    Circulation; 2018 Sep; 138(13):1304-1316. PubMed ID: 29735484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New Trends in Dyslipidemia Treatment.
    Jang AY; Lim S; Jo SH; Han SH; Koh KK
    Circ J; 2021 May; 85(6):759-768. PubMed ID: 33177309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New therapies targeting apoB metabolism for high-risk patients with inherited dyslipidaemias: what can the clinician expect?
    Sahebkar A; Watts GF
    Cardiovasc Drugs Ther; 2013 Dec; 27(6):559-67. PubMed ID: 23913122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.